July 16, 2019

Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

July 15, 2019 Press release - Non-regulatory Oslo, Norway, 15 July 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnol...
Read more
July 12, 2019

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

Paris, France, July 11, 2019, 5.45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developin...
Read more
July 11, 2019

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)

11.07.2019 14:32 Oslo, Norway, 11 July 2019 Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of...
Read more
July 11, 2019

Orexo Interim Report Q2 2019

Improving all fundamentals Q2 2019 highlights Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 3...
Read more
July 10, 2019

Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio

July 9, 2019 at 7:00 AM EDT PDF Version Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary cau...
Read more
July 10, 2019

Orexo prepays part of the corporate bond loan

Uppsala, Sweden – July 9, 2019 – Orexo AB (publ.) has resolved to prepay SEK 32.5 million, corresponding to 10 percent, of the unsecured corporate bond loan of in total SEK 32...
Read more
July 10, 2019

MIPS APPOINTS NEW CFO

MIPS AB (“MIPS”), a world leader in brain protection systems within helmet-based safety, today announces that Mats Juhl will assume the role as CFO of MIPS, replacing the previ...
Read more
July 9, 2019

Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma

July 8, 2019 Press release - Regulatory One complete response (CR) and two partial responses (PR) observed for the nine patients in part 1 (33% ORR), who receiv...
Read more
July 1, 2019

Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes

DUBLIN, Ireland and TREVOSE, Pa., July 01, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on ...
Read more
June 28, 2019

Oncopeptides has completed a directed share issue of approximately SEK 727 million

June 28, 2019 - Regulatory press release NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, ISRAEL, JAPAN, S...
Read more